Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CSF3R T618I |
Therapy | Ruxolitinib |
Indication/Tumor Type | chronic neutrophilic leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CSF3R T618I | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a clinical case study, Jakafi (ruxolitinib) treatment resulted in symptom improvement and decreased spleen and liver size lasting 5 months in a patient with chronic neutrophilic leukemia harboring CSF3R T618I along with SETBP1 G870S (PMID: 27068405). | 27068405 |
CSF3R T618I | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Case Reports/Case Series | Actionable | In a Phase II trial, Jakafi (ruxolitinib) treatment resulted in an overall hematologic response rate of 35% (15/43, 4 complete and 11 partial responses) and a median overall survival of 18.8 months in patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia harboring CSF3R mutations, including T618I (n=20), T640N (n=1), and T615A (n=1), with 2 complete and 9 partial responses in CNL patients harboring CSF3R T618I (PMID: 31880950; NCT02092324). | 31880950 |
PubMed Id | Reference Title | Details |
---|---|---|
(31880950) | Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | Full reference... |
(27068405) | Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. | Full reference... |